121 related articles for article (PubMed ID: 29096869)
21. Lipoprotein apheresis influences monocyte subpopulations.
Jellinghaus S; Reich C; Schatz U; Tselmin S; Ibrahim K; Pfluecke C; Schauer A; Bornstein SR; Hohenstein B; Strasser RH; Julius U; Poitz DM
Atheroscler Suppl; 2017 Nov; 30():108-114. PubMed ID: 29096825
[TBL] [Abstract][Full Text] [Related]
22. Direct adsorption of lipoproteins (DALI) from whole blood: first long-term clinical experience with a new LDL-apheresis system for the treatment of familial hypercholesterolaemia.
Jansen M; Banyai S; Schmaldienst S; Goldammer A; Rohac M; Hörl WH; Derfler K
Wien Klin Wochenschr; 2000 Jan; 112(2):61-9. PubMed ID: 10703153
[TBL] [Abstract][Full Text] [Related]
23. Defining the role of lipoprotein apheresis in the management of familial hypercholesterolemia.
Lee WP; Datta BN; Ong BB; Rees A; Halcox J
Am J Cardiovasc Drugs; 2011 Dec; 11(6):363-70. PubMed ID: 22149315
[TBL] [Abstract][Full Text] [Related]
24. Effects of Lipoprotein apheresis on the Lipoprotein(a) levels in the long run.
Groß E; Hohenstein B; Julius U
Atheroscler Suppl; 2015 May; 18():226-32. PubMed ID: 25936330
[TBL] [Abstract][Full Text] [Related]
25. Treatment of homozygous and double heterozygous familial hypercholesterolemic children with LDL-apheresis.
Stefanutti C; Vivenzio A; Colombo C; Di Giacomo S; Mazzarella B; Berni A; Nigri A; Koga N
Int J Artif Organs; 1995 Feb; 18(2):103-10. PubMed ID: 7558394
[TBL] [Abstract][Full Text] [Related]
26. Dextran-sulfate-adsorption of atherosclerotic lipoproteins from whole blood or separated plasma for lipid-apheresis--comparison of performance characteristics with DALI and Lipidfiltration.
Julius U; Parhofer KG; Heibges A; Kurz S; Klingel R; Geiss HC
J Clin Apher; 2007; 22(4):215-23. PubMed ID: 17455220
[TBL] [Abstract][Full Text] [Related]
27. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study.
Leebmann J; Roeseler E; Julius U; Heigl F; Spitthoever R; Heutling D; Breitenberger P; Maerz W; Lehmacher W; Heibges A; Klingel R;
Circulation; 2013 Dec; 128(24):2567-76. PubMed ID: 24056686
[TBL] [Abstract][Full Text] [Related]
28. [Epidemiological survey of lipid levels and factors in Kazakan people over 30-year old in Fukang of Xinjiang].
Liang DP; Yao XG; Li NF; Zhang DL; Guo YY; Lin L; Zhou L; Li WC; Yan ZT; Wang HM; Luo WL; Chang JH
Zhonghua Yu Fang Yi Xue Za Zhi; 2011 May; 45(5):440-3. PubMed ID: 21756789
[TBL] [Abstract][Full Text] [Related]
29. Rationale and design of MultiSELECt: A European Multicenter Study on the Effect of Lipoprotein(a) Elimination by lipoprotein apheresis on Cardiovascular outcomes.
Hohenstein B; Julius U; Lansberg P; Jaeger B; Mellwig KP; Weiss N; Graehlert X; Roeder I; Ramlow W
Atheroscler Suppl; 2017 Nov; 30():180-186. PubMed ID: 29096835
[TBL] [Abstract][Full Text] [Related]
30. Lipoprotein apheresis for Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease--Additional particular aspects of the Pro(a)LiFe multicenter trial.
Klingel R; Heibges A; Fassbender C
Atheroscler Suppl; 2015 May; 18():35-40. PubMed ID: 25936302
[TBL] [Abstract][Full Text] [Related]
31. Specific Lipoprotein(a) apheresis attenuates progression of carotid intima-media thickness in coronary heart disease patients with high lipoprotein(a) levels.
Ezhov MV; Safarova MS; Afanasieva OI; Pogorelova OA; Tripoten MI; Adamova IY; Konovalov GA; Balakhonova TV; Pokrovsky SN
Atheroscler Suppl; 2015 May; 18():163-9. PubMed ID: 25936321
[TBL] [Abstract][Full Text] [Related]
32. Adult dyslipidemia prediction is improved by repeated measurements in childhood and young adulthood. The Cardiovascular Risk in Young Finns Study.
Nuotio J; Oikonen M; Magnussen CG; Viikari JS; Hutri-Kähönen N; Jula A; Thomson R; Sabin MA; Daniels SR; Raitakari OT; Juonala M
Atherosclerosis; 2015 Apr; 239(2):350-7. PubMed ID: 25682034
[TBL] [Abstract][Full Text] [Related]
33. Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor? New Insights From the Framingham Offspring Study.
Bartlett J; Predazzi IM; Williams SM; Bush WS; Kim Y; Havas S; Toth PP; Fazio S; Miller M
Circ Cardiovasc Qual Outcomes; 2016 May; 9(3):206-212. PubMed ID: 27166203
[TBL] [Abstract][Full Text] [Related]
34. Transition from LDL apheresis to evolocumab in heterozygous FH is equally effective in lowering LDL, without lowering HDL cholesterol.
Lappegård KT; Enebakk T; Thunhaug H; Hovland A
Atherosclerosis; 2016 Aug; 251():119-123. PubMed ID: 27318831
[TBL] [Abstract][Full Text] [Related]
35. Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization.
Roeseler E; Julius U; Heigl F; Spitthoever R; Heutling D; Breitenberger P; Leebmann J; Lehmacher W; Kamstrup PR; Nordestgaard BG; Maerz W; Noureen A; Schmidt K; Kronenberg F; Heibges A; Klingel R;
Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):2019-27. PubMed ID: 27417585
[TBL] [Abstract][Full Text] [Related]
36. Lipoprotein(a), cardiovascular disease, and contemporary management.
Jacobson TA
Mayo Clin Proc; 2013 Nov; 88(11):1294-311. PubMed ID: 24182706
[TBL] [Abstract][Full Text] [Related]
37. Retrospective analysis of long-term lipid apheresis at a single center.
Koziolek MJ; Hennig U; Zapf A; Bramlage C; Grupp C; Armstrong VW; Strutz F; Müller GA
Ther Apher Dial; 2010 Apr; 14(2):143-52. PubMed ID: 20438535
[TBL] [Abstract][Full Text] [Related]
38. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
Wong ND; Chuang J; Zhao Y; Rosenblit PD
J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of lipid reduction with DALI and MONET.
Ramlow W; Röseler E; Heigl F; Spitthöver R; Ringel J; Schmitz G; Heinzler R; Abdul-Rahman N; Leistikow F; Himmelsbach F; Schettler V; Pham J; Kozik-Jaromin J
Atheroscler Suppl; 2017 Nov; 30():217-224. PubMed ID: 29096841
[TBL] [Abstract][Full Text] [Related]
40. Effects of lipoprotein apheresis on PCSK9 levels.
Julius U; Milton M; Stoellner D; Rader D; Gordon B; Polk D; Waldmann E; Parhofer KG; Moriarty PM
Atheroscler Suppl; 2015 May; 18():180-6. PubMed ID: 25936324
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
